[{"orgOrder":0,"company":"Austrianova","sponsor":"Klothonova","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Austrianova","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Austrianova \/ Klothonova","highestDevelopmentStatusID":"4","companyTruncated":"Austrianova \/ Klothonova"}]

Find Clinical Drug Pipeline Developments & Deals by Austrianova

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AusBiotech
                          Not Confirmed
                          AusBiotech
                          Not Confirmed

                          Details : Klothonova will leverage Austrianova's cellencapsulation technology to develop and commercialize treatments targeting Alzheimer's, cancer, kidney, heart and other age-related conditions.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          September 18, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Klothonova

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank